Indian Drug Firms Call For Price Control Relaxation

28 November 1997

India's pharmaceutical industry is drawing up proposals for an easing ofdrug prices and other controls, with the alternative of complete price decontrol in exchange for the free supply of certain drugs to the government health service. Industry sources have said the value of the free supply could amount to 5%-10% of the industry's turnover of $175 million to $350 million.

The basis of the proposal is that the free supplies will guarantee the availability of cheap drugs to th poorest sections of the population. The joint secretary of the Ministry of Chemical responsible for drug issues, Shantanu Consul, said he had not yet received the industry proposals but added that if the present system of controls was found to be unsatisfactory, "it was necessary to look for alternatives." He said the decisions as to what drugs would go on the free list and the question of quantity could pose problems.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight